BiotechTube
Genomic Prediction

Genomic Prediction

San Francisco, United States· Est.
lifeview.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Genomic Prediction is a private, commercial-stage company providing sophisticated genetic screening services for the fertility market. Its core innovation is the application of polygenic risk scores (PRS) to embryo selection, moving beyond traditional PGT to assess risk for common diseases like diabetes, heart disease, and cancer. The company's business model is service-based, partnering with fertility clinics and offering tests directly to patients. While generating revenue, it faces significant regulatory, ethical, and market adoption challenges in a competitive landscape.

Reproductive HealthGenetic Disease

Technology Platform

Proprietary platform combining next-generation sequencing of embryo biopsies with bioinformatics and machine learning algorithms to provide preimplantation genetic testing (PGT), including polygenic risk scoring for common diseases (Embryo Health Score).

Funding History

2
Total raised:$20M
Series A$16M
Seed$4M

Opportunities

The growing global IVF and PGT market provides a large addressable base for core services.
The Embryo Health Score creates a novel, premium market segment by addressing parental desire to reduce risk of common chronic diseases, potentially commanding higher prices.
Integration with fertility benefit managers could facilitate broader patient access and smoother payment pathways.

Risk Factors

Significant ethical and regulatory risks surround polygenic embryo screening, including potential bans and public backlash.
The clinical utility and long-term predictive accuracy of embryo polygenic risk scores are unproven, posing a scientific and reputational risk.
The company operates in a competitive PGT market with large, established players.

Competitive Landscape

Genomic Prediction competes in the PGT market with large diagnostic players like CooperSurgical (Viafet) and Illumina, as well as many other specialized labs. Its primary differentiation is the Embryo Health Score for polygenic conditions, a niche with few direct competitors currently but subject to intense ethical scrutiny and potential future competition from firms developing similar PRS applications.

More companies in Diagnostics & Precision Medicine →More companies in United States →